Business
-
Microdose Therapeutx will now be able to offer the Nexus6 SmartinhalerLive technology as an integral component of its electronic dry powder inhaler. The Nexus6 technology will allow the Microdose DPI to provide real-time reporting of… Read more . . .
-
Summit Biosciences has received almost $150k in qualifying therapeutic discovery project (QTDP) grants for development of its synthetic THC nasal spray. According to Summit, it will use the money to hire new personnel for the… Read more . . .
-
German biotech company bitop AG announced that it has begun enrolling patients in a clinical trial of its Ectoin inhalation solution for the treatment of airway inflammation. In addition to the inhalation solution, bitop is… Read more . . .
-
The United States Patent and Trademark Office has found that Hovione’s method for making flumethasone and an analogue was not obvious, upholding the company’s patent. A previous reexamination based on a 2005 claim had found… Read more . . .
-
According to ISTA Pharmaceuticals, the company will file an Investigational New Drug (IND) application for its bepotastine nasal spray for allergic rhinitis by the end of this year. ISTA, which already markets a bepotastine opthalmic… Read more . . .
-
Strativa Pharmaceuticals has entered into an agreement with Swedish Orphan Biovitrum (Sobi) for the development and commercialization of Nascobal cyanocobalamin (Vitamin B12) nasal spray in Europe. Sobi plans to begin development for European approval in… Read more . . .
-
Daiichi Sankyo has begun marketing its single dose Inavir laninamivir octanoate DPI for the treatment of influenza in Japan. According to the company, it plans to supply a total of 4 million units for the… Read more . . .
-
Particle analysis company ChemImage has launched a new testing and consulting business called Gateway Analytical, based in Gibsonia, Pennsylvania. Gateway offers particle characterization using various spectroscopic and microscopic techniques, as well as regulatory consulting. Read… Read more . . .
-
A group of investors led by Vatera Healthcare Partners has added $69 million to Pearl Therapeutics’s funding, bringing the total to more than $102 million since 2007. Pearl’s lead candidate, PT003, a glycopyrrolate/formoterol MDI for… Read more . . .
-
Pfizer says that it is "reviewing strategic alternatives" for its Capsugel business and that divestiture is an option. Capsugel manufactures capsules, including Vcaps hypromellose capsules for inhalation applications, and the Xcelodose powder dispensing system. 2009… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA